You are here

Rheumatoid Arthritis Satisfaction Outcome Research

Last updated on December 5, 2018

FOR MORE INFORMATION
Study Location
Chonbuk National University Hospital
Jeonju, Jeollabuk-do, 561-712 Korea, Republic of
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
19 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Patients aged 19 years or older

2. Patients diagnosed with RA

3. Treatment groups:

1) Tofacitinib citrate users: Patients currently on treatment with tofacitinib citrate in
RA therapy for 6 months or more 2) Adalimumab users: Patients currently on treatment with
adalimumab in the RA therapy for 6 months or more 4. Reading and writing with enough
proficiency to complete assessment instruments in Korean

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Patients currently on tofacitinib citrate or adalimumab in RA treatment for 2 year or
more

2. Patients taking concomitant other DMARDs except MTX 

NCT03703817
Pfizer
Recruiting
Rheumatoid Arthritis Satisfaction Outcome Research

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Rheumatoid Arthritis, Inflammation
NCT00195364
All Genders
18+
Years
Madrid,
Juvenile Rheumatoid Arthritis
NCT00652925
All Genders
2+
Years
Multiple Sites
Rheumatoid Arthritis Satisfaction Outcome Research
Treatment Satisfaction Comparison Between Tofacitinib Citrate Users And Adalimumab Users With Rheumatoid Arthritis
RA satisfaction OR: This study aim to compare treatment satisfaction and quality of life between patients who have been using tofacitinib citrate and patients who have been using adalimumab for 6 months or more and less than 2 year in RA treatment of rheumatoid arthritis.
Not Provided
Observational
Observational Model: Other
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Probability Sample
The study population is RA patients who have been using tofacitinib citrate or adalimumab for 6 months or more and less than 2 year in RA treatment at participating institution
Rheumatoid Arthritis
Not Provided
  • tofacitinib citrate users
    patients who have been using tofacitinib citrate for 6 months or more and less than 2 year in RA patients
  • adalimumab users
    patients who have been using adalimumab for 6 months or more and less than 2 year in RA patients
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
840
Same as current
November 30, 2018
November 30, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients aged 19 years or older
  2. Patients diagnosed with RA
  3. Treatment groups:

1) Tofacitinib citrate users: Patients currently on treatment with tofacitinib citrate in RA therapy for 6 months or more 2) Adalimumab users: Patients currently on treatment with adalimumab in the RA therapy for 6 months or more 4. Reading and writing with enough proficiency to complete assessment instruments in Korean

Exclusion Criteria:

  1. Patients currently on tofacitinib citrate or adalimumab in RA treatment for 2 year or more
  2. Patients taking concomitant other DMARDs except MTX
Sexes Eligible for Study: All
19 Years and older   (Adult, Older Adult)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Korea, Republic of
 
 
NCT03703817
A3921304
RA SATISFACTION ( Other Identifier: Alias Study Number )
Not Provided
Studies a U.S. FDA-regulated Drug Product: No
Plan to Share IPD: No
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
Pfizer
Pfizer
  • Department of Biostatistics, Korea University
  • The way communication (CRO)
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
October 2018

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now